spesolimab   Click here for help

GtoPdb Ligand ID: 12169

Synonyms: BI-655130 | BI655130 | spesolimab-sbzo | Spevigo®
Approved drug Immunopharmacology Ligand
spesolimab is an approved drug (FDA and EMA (2022))
Compound class: Antibody
Comment: Spesolimab (BI-655130) is a monoclonal antibody that disrupts interleukin-36 (IL-36)/IL-36 receptor signalling. Blocking this pathway is a molecular mechanism with potential to treat inflammatory diseases in skin and other epithelial tissues [2-3,5,7], since IL-36R expression is restricted to epithelial cells that are in direct contact with the environment, including those in the skin. Spesolimab (BI-655130) appears to be related to MAB92 which was reported by Boehringer Ingelheim in 2017 [6], but we have been unable to perform direct sequence matches. The heavy and light chain sequences for spesolimab (from its INN record) are claimed in Boehringer Ingelheim's patent US9023995B2 [4].
Click here for help
Classification Click here for help
Compound class Antibody
Approved drug? Yes. EMA (2022)  |  FDA (2022)  |  China NMPA (2024)
International Nonproprietary Names Click here for help
INN number INN
10845 spesolimab
Synonyms Click here for help
BI-655130 | BI655130 | spesolimab-sbzo | Spevigo®
Database Links Click here for help
Specialist databases
IMGT/mAb-DB 860
Other databases
GtoPdb PubChem SID 472319291
Search PubMed clinical trials spesolimab
Search PubMed titles spesolimab
Search PubMed titles/abstracts spesolimab